{"ticker": {"uuid": "b654bcea-0a35-4acf-84ce-54ad04fc2537", "symbol": "AURA", "name": "Aura Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Aura Minerals bounces back from recent drop with 7% advance (AUGO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUjlrWHNTUW85d3l6dEQ2bFE4TFdWcEFIWXpWdUt4Vi1KQnFPNXpuR3BacEIwdTQwajhpSzVzRmlqOG1iOXdISXNQbGFXZk9iM2gxZmZTZEdaR2g5TjZMQnoyLS1xZW5mcUxjWmdoX0FqYnd0VEZDaGF5VDM5bFFIUnQxMHZMVzJYUV9pU3BvTWVtY0pESzh3QUh4bkM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T21:05:53+00:00", "published_display": "14 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aura Biosciences, Inc. \u2013 NASDAQ:AURA", "summary": "This page displays the \"Price to earnings forward\" metric for Aura Biosciences, Inc. (NASDAQ: AURA). It appears to be a financial data point provided by TradingView, sourcing data from ICE Data Services and FactSet. The core content focuses solely on this specific financial metri", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T13:41:50", "published_display": "14 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Aura Biosciences, Inc. \u2013 NASDAQ:AURA", "summary": "This article provides a brief mention of Aura Biosciences, Inc. (NASDAQ: AURA) and its \"Price to sales forward\" metric within the context of TradingView's financial data platform. It highlights that the market was closed at the time of the article and provides no specific numeric", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:11:06", "published_display": "13 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director", "summary": "Aura Biosciences (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director to its Board of Directors, expanding the board from six to seven members. Dr. Bender will also serve on the Compensation and Nominating and Corporate Governance Committe", "url": "https://www.stocktitan.net/sec-filings/AURA/8-k-aura-biosciences-inc-reports-material-event-7ac1248d790b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:17:42", "published_display": "08 Jul 2026 23:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aura Biosciences Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Aura Biosciences Inc. related to activity on July 8. The news, published by Investing.com, indicates routine financial disclosure for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-aura-biosciences-inc-for-8-july-93CH-2591664", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:17:42", "published_display": "08 Jul 2026 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant", "summary": "Aura Biosciences, Inc. director Jeremy Bender was granted equity awards consisting of 30,000 restricted stock units (RSUs) and 60,000 stock options. The RSUs and stock options will vest in three substantially equal annual installments, contingent upon his continued service. The s", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-04755a59a63c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:24", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender", "summary": "Aura Biosciences (NASDAQ: AURA) has filed an initial Form 3 for its new director, Jeremy Bender. This filing establishes Bender as a reporting person with the SEC, indicating his director status but showing no initial beneficial ownership of shares or derivative positions. The Fo", "url": "https://www.stocktitan.net/sec-filings/AURA/form-3-aura-biosciences-inc-initial-statement-of-beneficial-ownership-dc2d05a21b70.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:24", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences adds biotech veteran Bender as bel-sar nears approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQX3JYbFN5V1dGa0duYTlXa0MxZVNmOEFDV19FbkY2NmJvcjhseEdVN25kMjFnWlVQSTdjc2VMREpVWF9CZWI3b21kVWZETEFGWVhUS2pGcVJJbWVVdTlfeTgxN3dKOEdSOWJwWUdvMUljWUZNcUxYaVRsc2FUcHZSS3YzalNpZjE1ZlRpZE9NanNyWGVySmkwVDJFaXBITXJ6Qm5NWEVvcUR2azlXVWFMYnNMeGxRaDYyQUFuekx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:01:00+00:00", "published_display": "08 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors", "summary": "Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Dr. Bender brings extensive experience in advancing innovative therapies through development and commercialization, especially in rare oncology. His appointment comes as Aura Biosciences nears", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323962/0/en/aura-biosciences-announces-appointment-of-jeremy-bender-ph-d-m-b-a-to-board-of-directors.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:00:33", "published_display": "08 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock", "summary": "This article discusses the recent insider selling activity at Aura Biosciences, where insiders sold US$939k worth of stock. The sale occurred between US$16.52 and US$27.00 per share, with the stock currently trading at US$17.15, suggesting the insiders made a timely decision to s", "url": "https://news.futunn.com/en/post/75525347/aura-biosciences-insiders-made-a-wise-decision-by-selling-us", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-07T11:40:33", "published_display": "07 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (AURA) That Institutions Follow", "summary": "This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide technical signals for institutional trading strategies. Key findings include strong near and mid-term sentiment, resistance testing, and an exceptional risk-reward short setup. The report detail", "url": "https://news.stocktradersdaily.com/news_release/20/The_Technical_Signals_Behind_AURA_That_Institutions_Follow_070526111802_1783307882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:10:47", "published_display": "06 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Aura Biosciences, Inc. (AURA)", "summary": "This article examines the historical performance of investing $1,000 in Aura Biosciences, Inc. (AURA) at various points in time. It details the company's focus on developing precision therapies for solid tumors, particularly its lead product candidate bel-sar for ocular oncology ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/AURA", "source_name": "Stock Titan", "published_at": "2026-07-04T10:39:34", "published_display": "04 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k", "summary": "Insiders at Aura Biosciences divested US$939k worth of stock over the last 12 months, with a significant portion occurring in the last quarter. While shareholders recently saw a 13% stock price increase, the consistent insider selling below the current price, coupled with low ins", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aura/aura-biosciences/news/more-money-in-the-bank-for-aura-biosciences-insiders-who-div", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:10:47", "published_display": "03 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive at Aura Biosciences (AURA) receives 14,858 RSUs", "summary": "Conor Kilroy, an officer at Aura Biosciences, has received a grant of 14,858 restricted stock units (RSUs) as part of the company's 2021 Stock Option and Incentive Plan, at no cash cost. These RSUs will vest in two equal annual installments starting July 15, 2027, provided Kilroy", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-73bacce0646d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:35:42", "published_display": "01 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com", "summary": "This article announces the filing of Form DEF 14A by AURA BIOSCIENCES for June 29. It briefly highlights the company's stock performance, showing a 15.01% gain, and points readers to additional financial market data and tools available on Investing.com.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-aura-biosciences-for-29-june-93CH-2579014", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T10:09:55", "published_display": "30 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzF5WVJ3N1JxT3gzWEUzNTduLU95UVhiV3VtTHhKQlc0OGUtaFhLQXRMdUNXWjBva1FPRmVuX2o0ekZQbTlWSHNQNDB0N0hOeFA1QjZlUWVibFBqTDk2cWNtUFJKbnNhUlVUVmR3RHdsUkdHZ0hfYU9YaVBSbExKVG9mZmJDX1NHS3JHZnNLT19jeGxrSUFQY1NFeXNIT1pLNFJDVUhVSEZJNWZWNFRVSXZhUVVUejc0aGNzZXMwXzdoN2M3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak", "summary": "Aura Biosciences is holding a virtual special stockholder meeting on August 5, 2026, to vote on two key proposals. These proposals include increasing the authorized common shares from 150 million to 500 million and amending the 2021 Stock Option and Incentive Plan to include pre-", "url": "https://www.stocktitan.net/sec-filings/AURA/def-14a-aura-biosciences-inc-definitive-proxy-statement-2b7972e13fd7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:41:08", "published_display": "29 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc Actuals & Estimates (BOATS:AURA)", "summary": "This article provides an overview of Aura Biosciences, Inc. (AURA) stock, including financial actuals and analyst estimates. It highlights the company's past earnings, revenue, and stock price performance, along with forecasts for future prices and upcoming earnings dates. The ar", "url": "https://www.tradingview.com/symbols/BOATS-AURA/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T21:41:01", "published_display": "26 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA)", "summary": "This article provides an overview of Aura Biosciences, Inc. (NASDAQ: AURA) stock, including its current price, market capitalization, analyst forecasts, and recent financial performance. It highlights that analysts predict a maximum price of $24.00 and a minimum of $15.00 for AUR", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:00", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AURA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Aura Biosciences, Inc. (AURA) stock, including analyst price targets, past performance, and key financial metrics. It highlights that analysts have a maximum price estimate of $24.00 and a minimum of $15.00 for AURA, while the stock has shown ", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:00", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones", "summary": "This article provides an in-depth analysis of Aura Biosciences Inc. (AURA) stock, highlighting a current mid-channel oscillation pattern and divergent sentiment readings. It outlines three distinct AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Aura_Biosciences_Inc._AURA_Risk_Zones_062426101002_1782353402.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-24T22:10:00", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Aura Biosciences Inc. (AURA) focusing on its dividend and stock split history. It indicates that AURA has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The page also presents current stock per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aura/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:20", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc (AURA) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Aura Biosciences Inc. (AURA), alongside a list of its major institutional shareholders and their shareholdings. The data includes the number of shares held by firms like Frazier Life Sciences Management, Adag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aura/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:32", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak", "summary": "Aura Biosciences is seeking shareholder approval to increase its authorized common shares from 150 million to 500 million and to amend its 2021 Stock Option and Incentive Plan. The proposed charter amendment aims to provide flexibility for future capital raising, acquisitions, an", "url": "https://www.stocktitan.net/sec-filings/AURA/pre-14a-aura-biosciences-inc-preliminary-proxy-statement-0049d5125a9a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:09:32", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding", "summary": "Aura Biosciences officer Anthony S. Gibney automatically sold 12,824 shares of common stock at $6.42 per share on June 16, 2026. This sale was conducted to cover tax withholding obligations arising from vested restricted stock units, and it was not a discretionary transaction. Fo", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-e90082d3de54.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:46", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares", "summary": "Aura Biosciences (AURA) has filed a Form 144 to report a proposed resale of 37,500 shares of common stock. These shares are associated with a restricted stock unit (RSU) award granted under the company's 2021 Stock Option and Incentive Plan, dated June 2, 2025. The Form 144 itsel", "url": "https://www.stocktitan.net/sec-filings/AURA/144-aura-biosciences-inc-sec-filing-85800a3f4eec.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:46", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) awards director RSUs and $6.21 stock options", "summary": "Aura Biosciences director Antony C. Mattessich was granted 15,000 Restricted Stock Units (RSUs) and stock options for 30,000 shares at an exercise price of $6.21 per share on June 11, 2026. These equity awards were granted under the company's 2021 Stock Option and Incentive Plan ", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-667847537b5f.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:10:15", "published_display": "15 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-completes-enrollment-phase-123933976.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:39:33+00:00", "published_display": "01 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-enrollment-completion-120000440.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances", "summary": "", "url": "https://finance.yahoo.com/m/016da1a6-ed01-3ca8-8c8d-6f9985691adb/aura-biosciences-gears-up-for.html", "source_name": "MarketBeat", "published_at": "2026-05-27T20:04:57+00:00", "published_display": "27 May 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data", "summary": "", "url": "https://finance.yahoo.com/m/aa12b1ed-17c9-31a7-bfab-dc8a515d0b7e/aura-biosciences-highlights.html", "source_name": "MarketBeat", "published_at": "2026-05-20T02:02:22+00:00", "published_display": "20 May 2026 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-inducement-grants-205000810.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:50:00+00:00", "published_display": "19 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aura Biosciences to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/aura-biosciences-participate-upcoming-investor-200100012.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-reports-first-quarter-200100974.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-closing-299-211500178.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T21:15:00+00:00", "published_display": "05 May 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Closing of $299 Million Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxObDNXVVRlUzFzRkNtRXpEeEFEVV9oMWlZY0ZSeHJORFJadjI5SDY1TERqNDJRQXpGdHZvamVDRlpZSWhhQzBVY1VkQnRGWUZSeG82bXVORktNT2l3cVdDcDUyY19DcFFHWXdSS1EyN2ZIZTFIbFV2aE5jcHBVMGdjOVdSTHJpQm0xNl9xT0VGZlhFNmhWM1NhY2JQRXZxdEJPeFl5MGRTUi1SRTBPbnBIMEtucGhHQk1WcjNQQlVrVEo1SkY4dUU1Sk1PeHZmRXZLWDFKTkVmbi1qR3dhaWhhVU95T2ZqR3hSN21WaVJ2QzBzUkZSZ0dxVkdZZGd5TGR2eUlObFhqMEotdkpYemgtR253RnBRY3hYVkpTRVRQaktRSm5xYmQwZ3JpVDQxZW80S08zRUd2Rm1Idw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Prices $260 Million Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aura-biosciences-prices-260-million-141900563.html", "source_name": "MT Newswires", "published_at": "2026-05-04T14:19:00+00:00", "published_display": "04 May 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWjlCU0d1NXBSUThCNnZlZ05QaFByVzYyUzBLT3hmU1NZTGxIaXZFMzNtb3VTMWNPUVRXSVZNVXRkbkhHQk5mc3Y5R3lyemNrX0YxMDlRTFhmY3ZTQ0pYbWV0Z1dsemxDbGh5Yy15Skl0ZDlsN1dmcmFFMVBBemtjYWlZNHlvbkNtR1hHY0tqSmVRMklObV84TTdUNWZXM3BnR3JhaWtmV2xhTEU?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPXy1BdDZOQ2lXSlpUM19WWlVsVkJDUTl2Y2RtcFZtUS1ESk52RXVuUHNDQ3lKU2tGSDdtaXoxQV9UNGhFZXMxeEhNcVFUQUtCR1NUb3lXOXVtbEtzeE5iWU5QN1I0R1lXa1F6MWF0QVV0VmY3T2dlX3dybDV0ODItdUE0WkI5NzZxQUtTRVF4Tm5YSl9seVBmQUdSbV9aM0UzYkVFSWt5VFNBbGlqakdHTk90Um0yUTJkTXlYbl9OcTFXb3pwTVJEWjVCY1NtM2hOb2tGRldpU2xobGdnUWxMRW5n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPREtGU1pOaHp1UW1IYVc1R1Z1MW1BYkthU1YyM1huektIQUoxaWl1eEU2TnAwaWs1Y0JSTmlCTl9lSi1TU0lvNDRHdVI5ZEh4TWVjOWhOV0x3UUpMZWFndUtGVE9UNDgwbUpQUzZScVZXWUpGcVo4MlBncTRWSU82MmxQYXgxQ1kwREF5QlVJaXJSUE1rOXg2MEdQU2N2RUxYTktjd0RB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQejZOaWhYQ3FudlZ2dTlKdXp0anhRM25tN3J1V0F3RlhJdzJqMlBYSnF3MFBEOFh0T0pIMTVTa2htdUNVblh1RThhcFpmZWJMMFAxT19YdFkyUlBLVEVQc3RBZDFtV2NHYmlLX0I3VUhSZG05dzZOcVFQbzBaVENWRjlRTUFuY1RfNlBFTEc4ZGJoaUVzY2FtNHd6Z2tzV2Yyc21sc0VUcw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aura Biosciences (AURA) insider\u2019s RSU tax sale covers 11,738 shares at ~$7", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPR2kxMW13Wmp3RXhLLUlaUHpkMFlFc1NqbXZhVUV6RE9YU0xiMzBOZzhWRHB3YThvUG9tQy04TTRLdGhVbGFjVnhYUHZ5emlSQWsyWTNWVmJrcEdaSGV0dWtiTFI2WTdWZWszSHZJdk1sYXFRVlN0ZVNZT0czM2JVTU1YRzNfV3lyOUtXMEEtaUU2cmlPV3FUdVFwOGFpbWZCbDNoNGRSZ2ZBb3BHam42LUZ5aXE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQb1ktbjR4QzRReE50Y2pJWjZPZGRwQW8zcVN3T0dzQTFoM040V1p1LUo2ZG1QT3pIMjRIU1Rfb1p1NzJvOEZ6bnNOWnNZRW9Cd3hUel9nUllXQ0E0SEdEUkZ5VGdlak5mOGlXQXhUOVcxZi1GZ21ET0N4aEdNT0RESHZfemtER2p3emc3Rm9ISGFzamlZRnFXZjJsbkRBQmdZSHh0REpZWm9pQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNR2N6NE5TUlhtV1Y5d2JvVkdYNlJDUlFCVDhJSkdfM1ZsVEJfTVZfS25zeWFZX21QSEJxZlVmMG1VaEFIZExkampZQm9fMndCSE1LUS0zTkRDQjNpRDc4Q04tZ1RESjRQOXMwaVpSdFJOeEZqSHJWenB3aUVGZmJpSUhyQjZteDF0M3d3NzFtdjEwT1NXbGJCalcwaWxYclIxR0ZRemYzTHBrS011TEtj?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Aura Minerals bounces back from recent drop with 7% advance (AUGO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUjlrWHNTUW85d3l6dEQ2bFE4TFdWcEFIWXpWdUt4Vi1KQnFPNXpuR3BacEIwdTQwajhpSzVzRmlqOG1iOXdISXNQbGFXZk9iM2gxZmZTZEdaR2g5TjZMQnoyLS1xZW5mcUxjWmdoX0FqYnd0VEZDaGF5VDM5bFFIUnQxMHZMVzJYUV9pU3BvTWVtY0pESzh3QUh4bkM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T21:05:53+00:00", "published_display": "14 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aura Biosciences, Inc. \u2013 NASDAQ:AURA", "summary": "This page displays the \"Price to earnings forward\" metric for Aura Biosciences, Inc. (NASDAQ: AURA). It appears to be a financial data point provided by TradingView, sourcing data from ICE Data Services and FactSet. The core content focuses solely on this specific financial metri", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T13:41:50", "published_display": "14 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aura Biosciences, Inc. \u2013 NASDAQ:AURA", "summary": "This article provides a brief mention of Aura Biosciences, Inc. (NASDAQ: AURA) and its \"Price to sales forward\" metric within the context of TradingView's financial data platform. It highlights that the market was closed at the time of the article and provides no specific numeric", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:11:06", "published_display": "13 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director", "summary": "Aura Biosciences (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director to its Board of Directors, expanding the board from six to seven members. Dr. Bender will also serve on the Compensation and Nominating and Corporate Governance Committe", "url": "https://www.stocktitan.net/sec-filings/AURA/8-k-aura-biosciences-inc-reports-material-event-7ac1248d790b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:17:42", "published_display": "08 Jul 2026 23:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aura Biosciences Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for Aura Biosciences Inc. related to activity on July 8. The news, published by Investing.com, indicates routine financial disclosure for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-aura-biosciences-inc-for-8-july-93CH-2591664", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:17:42", "published_display": "08 Jul 2026 23:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant", "summary": "Aura Biosciences, Inc. director Jeremy Bender was granted equity awards consisting of 30,000 restricted stock units (RSUs) and 60,000 stock options. The RSUs and stock options will vest in three substantially equal annual installments, contingent upon his continued service. The s", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-04755a59a63c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:24", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender", "summary": "Aura Biosciences (NASDAQ: AURA) has filed an initial Form 3 for its new director, Jeremy Bender. This filing establishes Bender as a reporting person with the SEC, indicating his director status but showing no initial beneficial ownership of shares or derivative positions. The Fo", "url": "https://www.stocktitan.net/sec-filings/AURA/form-3-aura-biosciences-inc-initial-statement-of-beneficial-ownership-dc2d05a21b70.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:24", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences adds biotech veteran Bender as bel-sar nears approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQX3JYbFN5V1dGa0duYTlXa0MxZVNmOEFDV19FbkY2NmJvcjhseEdVN25kMjFnWlVQSTdjc2VMREpVWF9CZWI3b21kVWZETEFGWVhUS2pGcVJJbWVVdTlfeTgxN3dKOEdSOWJwWUdvMUljWUZNcUxYaVRsc2FUcHZSS3YzalNpZjE1ZlRpZE9NanNyWGVySmkwVDJFaXBITXJ6Qm5NWEVvcUR2azlXVWFMYnNMeGxRaDYyQUFuekx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:01:00+00:00", "published_display": "08 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors", "summary": "Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Dr. Bender brings extensive experience in advancing innovative therapies through development and commercialization, especially in rare oncology. His appointment comes as Aura Biosciences nears", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323962/0/en/aura-biosciences-announces-appointment-of-jeremy-bender-ph-d-m-b-a-to-board-of-directors.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:00:33", "published_display": "08 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock", "summary": "This article discusses the recent insider selling activity at Aura Biosciences, where insiders sold US$939k worth of stock. The sale occurred between US$16.52 and US$27.00 per share, with the stock currently trading at US$17.15, suggesting the insiders made a timely decision to s", "url": "https://news.futunn.com/en/post/75525347/aura-biosciences-insiders-made-a-wise-decision-by-selling-us", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-07T11:40:33", "published_display": "07 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (AURA) That Institutions Follow", "summary": "This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide technical signals for institutional trading strategies. Key findings include strong near and mid-term sentiment, resistance testing, and an exceptional risk-reward short setup. The report detail", "url": "https://news.stocktradersdaily.com/news_release/20/The_Technical_Signals_Behind_AURA_That_Institutions_Follow_070526111802_1783307882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T11:10:47", "published_display": "06 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Aura Biosciences, Inc. (AURA)", "summary": "This article examines the historical performance of investing $1,000 in Aura Biosciences, Inc. (AURA) at various points in time. It details the company's focus on developing precision therapies for solid tumors, particularly its lead product candidate bel-sar for ocular oncology ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/AURA", "source_name": "Stock Titan", "published_at": "2026-07-04T10:39:34", "published_display": "04 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k", "summary": "Insiders at Aura Biosciences divested US$939k worth of stock over the last 12 months, with a significant portion occurring in the last quarter. While shareholders recently saw a 13% stock price increase, the consistent insider selling below the current price, coupled with low ins", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aura/aura-biosciences/news/more-money-in-the-bank-for-aura-biosciences-insiders-who-div", "source_name": "Simply Wall Street", "published_at": "2026-07-03T11:10:47", "published_display": "03 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive at Aura Biosciences (AURA) receives 14,858 RSUs", "summary": "Conor Kilroy, an officer at Aura Biosciences, has received a grant of 14,858 restricted stock units (RSUs) as part of the company's 2021 Stock Option and Incentive Plan, at no cash cost. These RSUs will vest in two equal annual installments starting July 15, 2027, provided Kilroy", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-73bacce0646d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:35:42", "published_display": "01 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com", "summary": "This article announces the filing of Form DEF 14A by AURA BIOSCIENCES for June 29. It briefly highlights the company's stock performance, showing a 15.01% gain, and points readers to additional financial market data and tools available on Investing.com.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-aura-biosciences-for-29-june-93CH-2579014", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T10:09:55", "published_display": "30 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzF5WVJ3N1JxT3gzWEUzNTduLU95UVhiV3VtTHhKQlc0OGUtaFhLQXRMdUNXWjBva1FPRmVuX2o0ekZQbTlWSHNQNDB0N0hOeFA1QjZlUWVibFBqTDk2cWNtUFJKbnNhUlVUVmR3RHdsUkdHZ0hfYU9YaVBSbExKVG9mZmJDX1NHS3JHZnNLT19jeGxrSUFQY1NFeXNIT1pLNFJDVUhVSEZJNWZWNFRVSXZhUVVUejc0aGNzZXMwXzdoN2M3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak", "summary": "Aura Biosciences is holding a virtual special stockholder meeting on August 5, 2026, to vote on two key proposals. These proposals include increasing the authorized common shares from 150 million to 500 million and amending the 2021 Stock Option and Incentive Plan to include pre-", "url": "https://www.stocktitan.net/sec-filings/AURA/def-14a-aura-biosciences-inc-definitive-proxy-statement-2b7972e13fd7.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:41:08", "published_display": "29 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc Actuals & Estimates (BOATS:AURA)", "summary": "This article provides an overview of Aura Biosciences, Inc. (AURA) stock, including financial actuals and analyst estimates. It highlights the company's past earnings, revenue, and stock price performance, along with forecasts for future prices and upcoming earnings dates. The ar", "url": "https://www.tradingview.com/symbols/BOATS-AURA/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T21:41:01", "published_display": "26 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA)", "summary": "This article provides an overview of Aura Biosciences, Inc. (NASDAQ: AURA) stock, including its current price, market capitalization, analyst forecasts, and recent financial performance. It highlights that analysts predict a maximum price of $24.00 and a minimum of $15.00 for AUR", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:00", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AURA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Aura Biosciences, Inc. (AURA) stock, including analyst price targets, past performance, and key financial metrics. It highlights that analysts have a maximum price estimate of $24.00 and a minimum of $15.00 for AURA, while the stock has shown ", "url": "https://www.tradingview.com/symbols/NASDAQ-AURA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:00", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones", "summary": "This article provides an in-depth analysis of Aura Biosciences Inc. (AURA) stock, highlighting a current mid-channel oscillation pattern and divergent sentiment readings. It outlines three distinct AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Aura_Biosciences_Inc._AURA_Risk_Zones_062426101002_1782353402.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-24T22:10:00", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Aura Biosciences Inc. (AURA) focusing on its dividend and stock split history. It indicates that AURA has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The page also presents current stock per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aura/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:20", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc (AURA) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Aura Biosciences Inc. (AURA), alongside a list of its major institutional shareholders and their shareholdings. The data includes the number of shares held by firms like Frazier Life Sciences Management, Adag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aura/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:32", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak", "summary": "Aura Biosciences is seeking shareholder approval to increase its authorized common shares from 150 million to 500 million and to amend its 2021 Stock Option and Incentive Plan. The proposed charter amendment aims to provide flexibility for future capital raising, acquisitions, an", "url": "https://www.stocktitan.net/sec-filings/AURA/pre-14a-aura-biosciences-inc-preliminary-proxy-statement-0049d5125a9a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:09:32", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding", "summary": "Aura Biosciences officer Anthony S. Gibney automatically sold 12,824 shares of common stock at $6.42 per share on June 16, 2026. This sale was conducted to cover tax withholding obligations arising from vested restricted stock units, and it was not a discretionary transaction. Fo", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-e90082d3de54.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:46", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares", "summary": "Aura Biosciences (AURA) has filed a Form 144 to report a proposed resale of 37,500 shares of common stock. These shares are associated with a restricted stock unit (RSU) award granted under the company's 2021 Stock Option and Incentive Plan, dated June 2, 2025. The Form 144 itsel", "url": "https://www.stocktitan.net/sec-filings/AURA/144-aura-biosciences-inc-sec-filing-85800a3f4eec.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:46", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) awards director RSUs and $6.21 stock options", "summary": "Aura Biosciences director Antony C. Mattessich was granted 15,000 Restricted Stock Units (RSUs) and stock options for 30,000 shares at an exercise price of $6.21 per share on June 11, 2026. These equity awards were granted under the company's 2021 Stock Option and Incentive Plan ", "url": "https://www.stocktitan.net/sec-filings/AURA/form-4-aura-biosciences-inc-insider-trading-activity-667847537b5f.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:10:15", "published_display": "15 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-completes-enrollment-phase-123933976.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:39:33+00:00", "published_display": "01 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-enrollment-completion-120000440.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances", "summary": "", "url": "https://finance.yahoo.com/m/016da1a6-ed01-3ca8-8c8d-6f9985691adb/aura-biosciences-gears-up-for.html", "source_name": "MarketBeat", "published_at": "2026-05-27T20:04:57+00:00", "published_display": "27 May 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data", "summary": "", "url": "https://finance.yahoo.com/m/aa12b1ed-17c9-31a7-bfab-dc8a515d0b7e/aura-biosciences-highlights.html", "source_name": "MarketBeat", "published_at": "2026-05-20T02:02:22+00:00", "published_display": "20 May 2026 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-inducement-grants-205000810.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:50:00+00:00", "published_display": "19 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/news/aura-biosciences-participate-upcoming-investor-200100012.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-reports-first-quarter-200100974.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aura-biosciences-announces-closing-299-211500178.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T21:15:00+00:00", "published_display": "05 May 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Closing of $299 Million Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxObDNXVVRlUzFzRkNtRXpEeEFEVV9oMWlZY0ZSeHJORFJadjI5SDY1TERqNDJRQXpGdHZvamVDRlpZSWhhQzBVY1VkQnRGWUZSeG82bXVORktNT2l3cVdDcDUyY19DcFFHWXdSS1EyN2ZIZTFIbFV2aE5jcHBVMGdjOVdSTHJpQm0xNl9xT0VGZlhFNmhWM1NhY2JQRXZxdEJPeFl5MGRTUi1SRTBPbnBIMEtucGhHQk1WcjNQQlVrVEo1SkY4dUU1Sk1PeHZmRXZLWDFKTkVmbi1qR3dhaWhhVU95T2ZqR3hSN21WaVJ2QzBzUkZSZ0dxVkdZZGd5TGR2eUlObFhqMEotdkpYemgtR253RnBRY3hYVkpTRVRQaktRSm5xYmQwZ3JpVDQxZW80S08zRUd2Rm1Idw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Prices $260 Million Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aura-biosciences-prices-260-million-141900563.html", "source_name": "MT Newswires", "published_at": "2026-05-04T14:19:00+00:00", "published_display": "04 May 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWjlCU0d1NXBSUThCNnZlZ05QaFByVzYyUzBLT3hmU1NZTGxIaXZFMzNtb3VTMWNPUVRXSVZNVXRkbkhHQk5mc3Y5R3lyemNrX0YxMDlRTFhmY3ZTQ0pYbWV0Z1dsemxDbGh5Yy15Skl0ZDlsN1dmcmFFMVBBemtjYWlZNHlvbkNtR1hHY0tqSmVRMklObV84TTdUNWZXM3BnR3JhaWtmV2xhTEU?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPXy1BdDZOQ2lXSlpUM19WWlVsVkJDUTl2Y2RtcFZtUS1ESk52RXVuUHNDQ3lKU2tGSDdtaXoxQV9UNGhFZXMxeEhNcVFUQUtCR1NUb3lXOXVtbEtzeE5iWU5QN1I0R1lXa1F6MWF0QVV0VmY3T2dlX3dybDV0ODItdUE0WkI5NzZxQUtTRVF4Tm5YSl9seVBmQUdSbV9aM0UzYkVFSWt5VFNBbGlqakdHTk90Um0yUTJkTXlYbl9OcTFXb3pwTVJEWjVCY1NtM2hOb2tGRldpU2xobGdnUWxMRW5n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPREtGU1pOaHp1UW1IYVc1R1Z1MW1BYkthU1YyM1huektIQUoxaWl1eEU2TnAwaWs1Y0JSTmlCTl9lSi1TU0lvNDRHdVI5ZEh4TWVjOWhOV0x3UUpMZWFndUtGVE9UNDgwbUpQUzZScVZXWUpGcVo4MlBncTRWSU82MmxQYXgxQ1kwREF5QlVJaXJSUE1rOXg2MEdQU2N2RUxYTktjd0RB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQejZOaWhYQ3FudlZ2dTlKdXp0anhRM25tN3J1V0F3RlhJdzJqMlBYSnF3MFBEOFh0T0pIMTVTa2htdUNVblh1RThhcFpmZWJMMFAxT19YdFkyUlBLVEVQc3RBZDFtV2NHYmlLX0I3VUhSZG05dzZOcVFQbzBaVENWRjlRTUFuY1RfNlBFTEc4ZGJoaUVzY2FtNHd6Z2tzV2Yyc21sc0VUcw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aura Biosciences (AURA) insider\u2019s RSU tax sale covers 11,738 shares at ~$7", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPR2kxMW13Wmp3RXhLLUlaUHpkMFlFc1NqbXZhVUV6RE9YU0xiMzBOZzhWRHB3YThvUG9tQy04TTRLdGhVbGFjVnhYUHZ5emlSQWsyWTNWVmJrcEdaSGV0dWtiTFI2WTdWZWszSHZJdk1sYXFRVlN0ZVNZT0czM2JVTU1YRzNfV3lyOUtXMEEtaUU2cmlPV3FUdVFwOGFpbWZCbDNoNGRSZ2ZBb3BHam42LUZ5aXE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQb1ktbjR4QzRReE50Y2pJWjZPZGRwQW8zcVN3T0dzQTFoM040V1p1LUo2ZG1QT3pIMjRIU1Rfb1p1NzJvOEZ6bnNOWnNZRW9Cd3hUel9nUllXQ0E0SEdEUkZ5VGdlak5mOGlXQXhUOVcxZi1GZ21ET0N4aEdNT0RESHZfemtER2p3emc3Rm9ISGFzamlZRnFXZjJsbkRBQmdZSHh0REpZWm9pQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNR2N6NE5TUlhtV1Y5d2JvVkdYNlJDUlFCVDhJSkdfM1ZsVEJfTVZfS25zeWFZX21QSEJxZlVmMG1VaEFIZExkampZQm9fMndCSE1LUS0zTkRDQjNpRDc4Q04tZ1RESjRQOXMwaVpSdFJOeEZqSHJWenB3aUVGZmJpSUhyQjZteDF0M3d3NzFtdjEwT1NXbGJCalcwaWxYclIxR0ZRemYzTHBrS011TEtj?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 53, "sentiment_summary": {"positive": 7, "negative": 3, "neutral": 43, "score": 52, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.84, "latest_week": "2026-07-10", "one_week_move": -11.6, "four_week_move": 6.7, "twelve_week_move": -6.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.202849, "market_dynamics_buy_signal": false, "relative_strength": -7.403249, "fair_value_gap": -9.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 41.248, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.6% over one week, +6.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 10}, {"label": "GlobeNewswire", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-11.6% over one week, +6.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Aura Minerals bounces back from recent drop with 7% advance (AUGO:NASDAQ)"}], "updated_at": "2026-07-16T03:02:22.243656+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}